Nir Naor
Vermögen: 23 599 $ am 31.05.2026
Vermögen: 23 599 $ am 31.05.2026
Nir Naor is an Independent Director at Brainstorm Cell Therapeutics, Inc. since 2023.
Former positions include Chief Financial Officer at Axogen, Inc. from 2023 to 2025, Chief Financial Officer at QuVa Pharma, Inc. in 2023, Chief Financial Officer at HMNC Holding GmbH from 2021 to 2022, Chief Financial Officer at Arbor Pharmaceuticals, Inc. in 2021, Chief Financial Officer-US Americas at Molnlycke Health Care US LLC from 2017 to 2021, Chief Financial Officer-United States at UCB SA from 2012 to 2017, and Auditor at KPMG Corporate Finance LLC from 2001 to 2005.
Education includes undergraduate, graduate, and MBA degrees from Tel-Aviv University, a graduate degree from the University of Hamburg, and an MBA from the International Institute for Management Development.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.02.2026 | 31.465 ( 0,29 % ) | 23 599 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 20.06.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
| AXOGEN, INC. | Finanzdirektor/CFO | 11.05.2025 |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Medical SpecialtiesHealth Technology Manufactures sterile injectable products | Finanzdirektor/CFO | 01.09.2023 |
HMNC Holding GmbH
HMNC Holding GmbH Financial ConglomeratesFinance Provides investment services | Finanzdirektor/CFO | 01.10.2022 |
Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products which focuses on neuroscience, cardiovascular and pediatric markets | Finanzdirektor/CFO | 01.09.2021 |
Molnlycke Health Care US LLC
Molnlycke Health Care US LLC Medical SpecialtiesHealth Technology Manufactures surgical and wound care products | Corporate Officer/Principal | 01.01.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Brainstorm Cell Therapeutics, Inc.
Brainstorm Cell Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company, which develops innovative adult stem cell therapeutic products | Health Technology |
KPMG Corporate Finance LLC
KPMG Corporate Finance LLC Investment ManagersFinance Provides investment advice | Finance |
UCB SA
UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Hamburg
University of Hamburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Institute for Management Development
International Institute for Management Development Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molnlycke Health Care US LLC
Molnlycke Health Care US LLC Medical SpecialtiesHealth Technology Manufactures surgical and wound care products | Health Technology |
Axogen, Inc.
Axogen, Inc. Medical SpecialtiesHealth Technology Provides products and technologies for peripheral nerve reconstruction and regeneration | Health Technology |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Medical SpecialtiesHealth Technology Manufactures sterile injectable products | Health Technology |
Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products which focuses on neuroscience, cardiovascular and pediatric markets | Health Technology |
HMNC Holding GmbH
HMNC Holding GmbH Financial ConglomeratesFinance Provides investment services | Finance |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen